Immunotherapy with transplanted T-regulatory (Treg) cells is currently in use. However, patients have complex internal environments with confounding factors, including the presence of inflammatory cytokines. The present study aimed to detect Treg cell function under simulated inflammatory conditions to provide a foundation for Treg cell-based immunotherapy. CD4 + CD25 high Treg cells were sorted from peripheral blood mononuclear cells and cultured for 14 days in the presence of recombinant human interleukin-2 (rhIL-2) and anti-CD3/CD28 beads, with or without 25 ng/ml rhIL-6. Next, the absolute count of Treg cells was determined, the stability and activity were detected by measuring the expression levels of forkhead box (Fox)P3 and CD39, and the suppressive function of Treg cells was investigated by assessing the suppression of T-effector cell proliferation by Treg cells after co-culture for 5 days. The number of Treg cells cultured in the presence of 25 ng/ml rhIL-6 for 14 days was reduced by 49.7% when compared with that of cells cultured without rhIL-6. Of the Treg cells continually cultured for 14 days without or with 25 ng/ml rhIL-6, 56.15 and 24.7% expressed FoxP3, respectively. There was no difference in the activity of the FoxP3 + Treg cells after culture for 14 days without or with 25 ng/ml rhIL-6. The suppressive function of Treg cells tended to deteriorate in the presence of rhIL-6. In conclusion, IL-6 inhibited the proliferation and stability of Treg cells, suggesting that administration of increased numbers of Treg cells may be required during Treg cell-based immunotherapy.
Introduction

CD4
+ CD25 + forkhead box (Fox)P3 + T-regulatory (Treg) cells are an important subset of immune cells that may inhibit the activation, proliferation and cytokine secretion of other types of immune cell. Treg cells have an indispensable role in driving autoimmune tolerance and maintaining the immune balance in vivo (1) (2) (3) . Abnormal Treg cell functions are widely involved in the occurrence and development of numerous diseases (4) (5) (6) , and immunotherapy to recover the number and/or function of Treg cells is a good optional treatment for such diseases.
Immunotherapy with transplanted Treg cells has been used in autoimmune diseases and other immune-associated diseases, including type-1 diabetes mellitus, systemic lupus erythematosus (SLE) and graft vs. host disease (GVHD) (7) (8) (9) (10) (11) (12) (13) . Culturing sufficient numbers of Treg cells in vitro is the foundation of Treg-based immunotherapy, and maintaining the stable inhibitory function of Treg cells in vivo is pivotal for successful treatment (8, 9) . However, the stability and inhibitory function of Treg cells in the internal inflammatory environment requires further systematic investigation.
The internal environment of patients with autoimmune diseases is complex and there may be inflammation or elevated levels of inflammatory cytokines, including tumour necrosis factor-α, interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-23 (IL-23) and interferon-γ (IFN-γ) expressed in human atherosclerotic plaques (14, 15) ; interleukin-17 (IL-17), IFN-γ, IL-6 and IL-23 expressed in type 1 diabetes mellitus (16) ; IL-1β and IL-17 expressed in SLE (17) ; and IL-6 expressed in GVHD (9, 18) . IL-6 is the critical cytokine that mediates inflammation (18, 19) . As mentioned above, IL-6 is highly expressed in autoimmune diseases and GVHD (9, (14) (15) (16) 18) , and the inflammatory environment in vivo may be simulated by adding In the present study, the possible inflammatory environment was simulated in vitro by using recombinant human (rh)IL-6 to observe the absolute number, stability, activity and inhibitory function of Treg cells. The present study lays 
Stability and inhibitory function of Treg cells under inflammatory conditions in vitro
Materials and methods
Samples.
A total of eight healthy blood donors were recruited from Shaanxi Provincial People's Hospital Affiliated to Xi'an Medical University (Xi'an, China); the male/female ratio was 4:4, and the average age was 27.8±1.3 years. A total of 40 ml sterile peripheral venous blood samples (including heparin to prevent clotting) were collected from all healthy blood donors. The study was approved by the Ethics Committee of Xi'an Medical University (Xi'an, China; approval no. XYLS2019131).
According to the principle of informed consent, all healthy blood donors signed consent forms prior to collection of the peripheral blood samples. All of the experiments in this study were performed in accordance with the guidelines for blood sample collection approved by the Institutional Ethics Committee of Xi'an Medical University.
Isolation of peripheral blood mononuclear cells (PBMCs).
PBMCs were isolated from the samples via density-gradient centrifugation. First, 20 ml of Lymphoprep™ (Axis-Shield) was added to each centrifuge tube, and then, 20 ml of the individual peripheral blood sample diluted with an equal volume of PBS was slowly added. After centrifugation for 20 min at 500 x g under room temperature, the centrifuge tubes were gently removed and the monocyte suspension was isolated and washed with PBS. After the erythrocytes were lysed with FACS lysis solution (BD Biosciences), the isolated PBMCs were washed with PBS and then resuspended in PBS and counted.
Sorting of Treg cells and T-effector (Teff) cells. After 4x10 7
PBMCs were resuspended in RPMI 1640 Media supplemented with 10% fetal bovine serum and 100 U/ml penicillin and 100 mg/ml streptomycin (All Gibco; Thermo Fisher Scientific, Inc. /well) in a 96-well U-bottomed plate in the presence of 100, 300 or 500 U/ml rhIL-2 (HumanZyme; ProteinTech Group, Inc.) and anti-CD3/CD28 beads (Treg cells/beads ratio, 0.5:1, 1:1 or 2:1), with or without 25 ng/ml rhIL-6 (HumanZyme) under 37˚C in a humidified atmosphere containing 5% CO 2 . The cell concentration was 1x10 6 /ml and 100 µl/well. The Treg cell population was counted after culturing for 3, 5, 7, 10 and 14 days, the medium was replaced after culturing for 3, 5, 7 and 10 days with RPMI 1640 Media supplemented with 10% fetal bovine serum, 100 U/ml penicillin, 100 mg/ml streptomycin and corresponding concentrations of rhIL-2 and rhIL-6. 4 /well) in a 96-well U-bottomed plate in the presence of anti-CD3/CD28 beads (Teff cells/beads, 1:1), without or with 25 ng/ml rhIL-6. rhIL-2 was not added, as the Teff cells are able to secrete IL-2 after activation with anti-CD3/CD28 beads (24) . The Teff cell proliferation was determined by flow cytometry after Teff cells were cultured for 5 days. The proliferation curves of the Teff cells were fitted, and the Teff-cell proliferation were expressed as the response (R; the proportion of the precursor sample pool that responded to stimulation by dividing), doubling time (Td; the time required for the average responding T cell to achieve a single cell division) and the proliferative capacity (Cp) of the responding T cells in each sample. The methodology for calculating R, Td and Cp from the proliferation curves was described in detail in previous studies (24) (25) (26) .
Statistical analysis. All flow cytometry results of the present study were analysed with FlowJo software version 7.6.1 (FlowJo LLC). Calculations were performed using GraphPad Prism software, version 6 (GraphPad Software, Inc). Values are expressed as the mean ± standard error of the mean, the significance of differences between two groups were calculated using paired t-test and Student's unpaired 2-tailed t-te#st. The significance of differences among three groups was calculated using One-way ANOVA followed by Tukey's test. P<0.05 was considered to indicate a statistically significant difference. T-lymphocyte population was 72.2±2.8% (Fig. 1) .
Results
Sorting of Treg cells and Teff cells.
Optimum concentration of rhIL-2 and anti-CD3/CD28
beads for culture of Treg cells. The absolute counts of Treg cells cultured with 100, 300 or 500 U/ml rhIL-2 for 14 days in the presence of anti-CD3/CD28 beads (Treg cells/beads, 1:1) in vitro are presented in Fig. 2A . The number of Treg cells was 1x10 5 /well on day 0, except for the experiment for detection of inhibitory function. The number of Treg cells increased steadily until reaching a plateau ~day 10 after culturing in vitro. There were no differences among the counts of Treg cells cultured with 100, 300 or 500 U/ml rhIL-2 for 3 or 5 days. There was a significant difference between the counts of Treg cells cultured with 100 and 300 U/ml rhIL-2 for 7, 10 or 14 days. There was no difference between the counts of Treg cells cultured with 300 and 500 U/ml rhIL-2 for 7, 10 or 14 days.
The absolute counts of the Treg cells cultured for 14 days with anti-CD3/CD28 beads (Treg cells/beads, 0.5:1, 1:1 or 2:1) in the presence of 300 U/ml rhIL-2 in vitro are presented in Fig. 2B . The Treg cell counts also increased with culture time until plateauing ~day 10. There were no differences among the counts of Treg cells cultured in vitro, whether the ratio of cells to beads was 0.5:1, 1:1 or 2:1 during culture for 3 or 5 days. There was a significant difference between the counts of Treg cells cultured with beads at a 0.5:1 cell-to-bead ratio and those cultured with beads at a 1:1 cell-to-bead ratio at 7, 10 or 14 days. There was no difference in the counts between Treg cells cultured with beads at a 1:1 ratio and those cultured with beads at a 2:1 ratio at 7, 10 or 14 days.
The above results demonstrate that the absolute count of the Treg cells is significantly affected by the concentration of rhIL-2 and anti-CD3/CD28 beads; 300 U/ml rhIL-2 and a 1:1 cell/bead ratio are the optimal concentrations when the Treg cells are cultured in vitro, and 3.17±0.10x10 5 cells were obtained after 14 days of culture.
The Treg cell number is reduced under inflammatory conditions. The absolute counts of Treg cells cultured for 14 days in the presence of rhIL-2 (300 U/ml) and anti-CD3/CD28 beads (Treg cells/beads, 1:1), without or with 25 ng/ml rhIL-6 in vitro are presented in Fig. 3 . There was no difference in the counts of Treg cells cultured without and with 25 ng/ml rhIL-6 when cultured for <5 days in vitro. There was a significant difference in the counts of Treg cells cultured without and with 25 ng/ml rhIL-6 when cultured for >7 days (P<0.05). The number of Treg cells cultured in the presence of 25 ng/ml rhIL-6 for 14 days was reduced by 49.7% when compared with that of cells cultured without rhIL-6.
The stability of Treg cells declines under inflammatory
conditions. Treg cells were cultured (300 U/ml rhIL-2; Treg cells/beads, 1:1; without or with 25 ng/ml rhIL-6) for 14 days in vitro; the proportion of CD4 + FoxP3 + Treg cells within the total cell population of the well (thereafter referred to as total cell population) and the FoxP3 mean fluorescence intensity (MFI) of CD4 + FoxP3 + Treg cells are presented in Fig. 4A and B, respectively. The proportion of CD4 + FoxP3 + Treg cells was 98.0% on day 0, as the purity for sorted Treg cells was 98.0%. Regarding the proportion of CD4 + FoxP3 + Treg cells within the total cell population, there was a significant difference in the proportion of CD4 + FoxP3 + Treg cells cultured without and with 25 ng/ml rhIL-6 when cultured for 3, 5, 7, 10 and 14 days (P<0.05). In terms of the FoxP3 MFI of CD4 + FoxP3 + Treg cells, there was no difference between the cells cultured without and with 25 ng/ml rhIL-6, whether cultured for 3, 5, 7, 10 or 14 days in vitro.
Regarding the proportion of CD4 + FoxP3 + cells within the total cell population cultured in the presence of rhIL-2, which gradually declined over the 14-day culture period, the proportion of Treg cells cultured with rhIL-6 decreased much faster compared with the proportion of Treg cells cultured without rhIL-6 (Fig. 4A) . Among the Treg cells cultured without rhIL-6, there were always certain amounts of cells expressing FoxP3, although the proportion declined gradually, and the proportion of CD4 + FoxP3 + Treg cells within the total cell population was 56.2±2.7% after Treg cells were cultured for 14 days. However, FoxP3 expression decreased more rapidly in the Treg cells cultured with rhIL-6, and the proportion of CD4 + FoxP3 + Treg cells within the total cell population was 24.7±3.4% after Treg cells were cultured for 14 days, which suggests a lower stability of Treg cells in the inflammatory environment and that increased numbers of Treg cells should be used in treatments considering the complexity of the internal environments of patients. , without or with 25 ng/ml rhIL-6. Teff-cell proliferation was detected after culture for 5 days by gating on CFSE + cells, and the results of the corresponding R, Td, and Cp measurements were presented in Fig. 6 (24-26) .
The representative overlaid proliferation cur ve comparing Teff cells cultured alone and Teff cells co-cultured with Treg cells are presented in Fig. 6A , the proliferation of Teff cells was inhibited when co-cultured with Treg cells, independent of rhIL-6 presence (Fig. 6A) . As presented in Fig. 6B , the proportion of the precursor sample pool that responded to stimulation by dividing (R-value) did not change significantly when the Teff cells were co-cultured with Treg cells, regardless of rhIL-6 presence. In terms of the time required for the average responding T cell to achieve a single cell division the (Td value) shown in Fig. 6C , co-culture of Teff cells with Treg cells led to a significantly prolonged Td (P<0.05) in a manner that was independent of rhIL-6 presence. Regarding the proliferative capacity (Cp value) showed in Fig. 6D , co-culture with Treg cells led to a significantly decreased Cp (P<0.05) independent of rhIL-6 presence.
These results demonstrated that Treg cells exert suppressive effects on Teff cells in the presence or absence of rhIL-6. However, the inhibitory function of Treg cells may weaken in the presence of rhIL-6, which further suggests that increased numbers of Treg cells should be used for treatment considering the complexity of the internal environment of the patient.
Discussion
As an important inhibitory immune cell subset in vivo, Treg cells have great potential in the immunotherapy of various diseases, including autoimmune diseases (7) (8) (9) (10) . Considering the complex internal environment of patients, e.g. inflammatory conditions, the stability and inhibitory function of Treg cells under such conditions should be further investigated.
Transplanting a sufficiently large number of Treg cells is a key factor for successful immunotherapy of diseases, including autoimmune diseases. Although Treg cells may be easily cultured and amplified in vitro in the presence of IL-2 and anti-CD3/CD8 beads (19, 23, 28, 29) , the survival of Treg cells may be affected by inflammatory cytokines, including IL-6, in vivo (30) (31) (32) (33) . In the present study, the number of Treg cells cultured in the presence of 25 ng/ml rhIL-6 for 14 days was reduced by 49.7% when compared with that of cells cultured without rhIL-6, demonstrating the influence of the environment on Treg cell survival. Therefore, an increased number of Treg cells may be required for immunotherapy in patients with autoimmune diseases.
A sufficient number of Treg cells is the foundation of immunotherapy; more importantly, the stability and activity of Treg cells are directly associated with the effectiveness of treatment (34) . In the present study, 56.0 or 24.7% of Treg cells expressed the transcription factor FoxP3 after in vitro culture for 14 days without or with rhIL-6, respectively. These results indicate that Treg cells are a relatively stable cell subset, but their stability declined significantly under inflammatory conditions, further suggesting that for immunotherapy, transplantation of increased numbers of Treg cells is required.
The expression of CD39 on the Treg cell membrane suggests increased activity of Treg cells (25, 35) . In the present study, the proportion of CD39 expressed by FoxP3 of a previous study, which indicated that CD39 + Treg cells have a strong suppressive function even in the presence of inflammatory cytokines in vitro (36) .
Suppression of Teff cell proliferation is an important aspect of the inhibitory function of Treg cells. In the present study, Treg cells suppressed the proliferation of Teff cells, which is consistent with the previous results regarding the stability and activity of Treg cells cultured for 5 days. A decreasing trend regarding Treg cell suppression was observed in the presence of rhIL-6. The inhibitory function of Treg cells is directly linked to the treatment effect of Treg cell-based immunotherapy.
The present study systematically examined the absolute count, stability, activity and inhibitory function of Treg cells, and possible changes in Treg cell function in the presence of cytokines that simulate inflammatory environments were determined in vivo. To achieve good efficacy, transplantation of increased numbers of Treg cells may be a reasonable therapeutic approach for immunotherapy. The present study provides an important experimental basis for the development of Treg cell-based immunotherapy for various immune-associated diseases, including autoimmune diseases.
